A different perspective on Vietnam’s economy and doing business in Vietnam. Make sure to  subscribe.

Pharmaceutical products: Vietnam imports surge by 10.29 percent in May

Vietnam’s imports of pharmaceutical products reached US$369.17 million in May 2025, according to figures released by Vietnam’s General Department of Customs. This represents a significant increase of 10.29 percent compared to April, bringing the year-to-date (YTD) import value to US$1.66 billion.

Germany maintains its lead despite varied performance from top suppliers:

Germany remained the primary source for pharmaceutical product imports, with a May value of US$45.74 million, marking a 24.29 percent increase from April. While the USA saw a 14.13 percent decrease and Italy a 27.05 percent decrease, France surged by 97.19 percent to become the second-largest supplier in May, at US$44.65 million.

Extraordinary month-on-month surges from various markets:

Several countries exhibited remarkable month-on-month growth in May, often from lower bases:

  • Canada recorded an astonishing surge of 5742.95 percent, albeit from a very low base.
  • Pakistan imports jumped by 464.86 percent.
  • Ireland experienced a massive increase of 458.67 percent, reaching US$22.05 million, becoming a top 5 supplier for the month.
  • Hungary imports surged by 333.82 percent.
  • Thailand imports grew by 170.32 percent.
  • Australia saw a significant increase of 140.71 percent.
  • Switzerland imports grew by 120.85 percent.
  • Denmark and Indonesia also saw substantial increases.
  • The “Other” category also saw a notable increase of 11.28 percent.
  • Argentina and Philippines emerged as new suppliers in May after having no imports in April.

Significant decreases in imports:

Conversely, some markets faced substantial declines in imports in May:

  • Russia saw a drastic drop of 93.83 percent.
  • Spain imports decreased by 57.25 percent.
  • Poland imports fell by 55.80 percent.
  • Singapore imports decreased by 54.74 percent.
  • Taiwan imports decreased by 50.06 percent.
  • Japan and Cyprus also experienced notable decreases.
  • Bangladesh saw a decrease of 17.50 percent.

The overall strong increase in May’s pharmaceutical product imports indicates a robust and diversifying market in Vietnam, with significant contributions from various global suppliers, especially those experiencing explosive growth.

See also: Vietnam Pharmaceuticals Industry 2025: Growth, Imports & Key Players

Vietnam imports of pharmaceutical products, May 2025, US$ millions

MayAprilMoMYTD% of YTD
Total369.17334.7410.29%1,660.92100.00%
Other27.4224.6511.28%0.000.00%
Germany45.7436.8024.29%191.2411.51%
France44.6522.6497.19%166.5510.03%
USA44.3251.62-14.13%194.6711.72%
Italy23.3732.03-27.05%124.257.48%
Ireland22.053.95458.67%61.953.73%
India21.5624.77-12.97%118.217.12%
Switzerland14.706.66120.85%48.192.90%
Belgium14.5414.222.21%103.026.20%
Sweden13.2218.18-27.26%74.704.50%
Netherlands11.469.0826.19%44.882.70%
South Korea10.4510.380.69%48.482.92%
Thailand9.373.47170.32%35.642.15%
Austria8.886.6832.92%39.402.37%
Spain8.5319.96-57.25%48.952.95%
UK8.075.2254.56%35.362.13%
China6.434.7635.20%24.091.45%
Japan6.3710.52-39.45%25.551.54%
Hungary5.491.26333.82%16.160.97%
Australia4.711.96140.71%22.921.38%
Canada2.710.055742.95%5.930.36%
Denmark2.451.14115.33%9.530.57%
Poland2.174.91-55.80%21.241.28%
Cyprus1.613.02-46.59%10.520.63%
Turkey1.590.8195.03%8.930.54%
Indonesia1.450.7494.31%4.210.25%
Pakistan1.440.25464.86%4.630.28%
Singapore1.122.47-54.74%6.560.40%
Taiwan1.112.22-50.06%7.610.46%
Bangladesh0.821.00-17.50%4.320.26%
Russia0.538.65-93.83%21.861.32%
Lithuania0.430.430.37%0.860.05%
Malaysia0.270.2412.52%1.420.09%
Argentina0.120.000.00%3.650.22%
Philippines0.000.000.00%0.160.01%

Your support keeps this site independent and objective.
If you find value in this work, please consider making a contribution.

Need more convincing?

Our content is free because we believe a rising tide lifts all boats.

By making accurate, independent information accessible to everyone, we help create a more informed, resilient, and empowered business community.

When businesses, investors, policymakers, and everyday readers all have access to clear, unbiased analysis, it leads to better decisions, fairer opportunities, and stronger economic outcomes for all.

That said, while our content is free to read, it costs money to create.

Behind every article is careful research, fact-checking, and expert analysis — all of which require time, skill, and resources.

If you can spare a couple of dollars, your support helps ensure that reliable, unbiased information remains accessible to all.

Create your listing